The role of protein kinase C in the desensitization of rat pancreatic islets to cholinergic stimulation.
It is well known that protein kinase C (PKC) plays an important role in mediating insulin secretion in response to cholinergic stimulation. In various cells PKC also mediates a desensitization process. The role of PKC for homologous desensitization of the insulin response to repetitive stimulation with the muscarinic agonist carbachol (CCh) was investigated in perifusion experiments using isolated rat pancreatic islets. Repetitive (six times) stimulation with CCh (100 microM) reduced insulin secretion over time (up to 50% during the second challenge). This was not a toxic effect since the desensitizing effect was mostly washed out after 45 min. When PKC was downregulated by long term preincubation (20 h) with 200 nM phorbol 12-myristate 13-acetate (TPA), the initial stimulation of insulin release by CCh was reduced by 50%, and a desensitization by further CCh stimulation was no longer obvious. In contrast, when other compounds with different mechanisms of actions for inactivating PKC were used, i.e. PKC inhibitors such as staurosporin (100 nM), Ro 31-8220 (5 microM) or PKC peptide(19-31), the insulin secretion in response to CCh was reduced but the desensitization was not abolished. When PKC was downregulated or inhibited by the above methods, the PKC activator phorbol 12-myristate 13-acetate (TPA; 200 nM) was no longer able to evoke an increase in insulin secretion during static incubation, i.e. these control experiments indicate a real PKC inhibition. When heparin (50 microg/ml), an inhibitor of G-protein coupled receptor kinase (GRK), was used, the desensitization of the cholinergic stimulation of insulin release remained unchanged. The data indicate that PKC plays a role in CCh-mediated insulin secretion and also show a desensitization of this effect after repetitive stimulation with CCh. The data further indicate that specific PKC isoenzymes that are inhibited by staurosporin or Ro 31-8220 do not take part in the desensitization process, while isoenzymes that are downregulated by TPA are involved. It may be speculated that a hitherto unknown PKC isoenzyme that is downregulated by TPA but not by the other used PKC inhibitors is involved in the desensitization process, or that a nonspecific effect of TPA is involved. Members of the GRK family are not involved in the desensitization process of CCh.
Verspohl
E J
EJ
University of Münster, Institute of Pharmaceutical Sciences, Department of Pharmacology, Hittorfstr. 58-62, 48149 Münster, Germany.
Wienecke
A
A
D000704:Analysis of Variance; D000818:Animals; D002217:Carbachol / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D007211:Indoles / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology*; D010446:Peptide Fragments / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D019311:Staurosporine / Q000494:pharmacology; D013268:Stimulation, Chemical; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D004791:Enzyme Inhibitors; D007211:Indoles; D007328:Insulin; D018721:Muscarinic Agonists; D010446:Peptide Fragments; C073885:protein kinase C (19-31); D002217:Carbachol; D011493:Protein Kinase C; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate; C064758:Ro 31-8220